Research progress of parkin′s molecular structure and biological function and its role in kidney disease

doi:10.3877/cma.j.issn.2095-3216.2020.02.005

Abstract

Abstract:

Parkin is an E3 ubiquitin ligase, which can ubiquitinate a large number of cytoplasm proteins and mitochondrial outer membrane proteins, and has a wide range of important biological functions. It has been proved that parkin can mediate important biological processes such as targeted recognition and degradation of damaged mitochondria, gene transcription, translation, DNA repair, cell survival/death, cell proliferation, and inflammation. In recent years, parkin′s roles in renal disease have attracted increasing attention. In this paper, parkin′s molecular structure, biological functions, and its roles in renal disease were introduced.

Key words: Parkin, E3 ubiquitin ligase, Kidney disease

Ling Wang, Yani He. Research progress of parkin′s molecular structure and biological function and its role in kidney disease[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2020, 09(02): 74-77.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2020.02.005

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2020/V09/I02/74

Figures/Tables 3

References 40

[1]	Kitada T, Asakawa S, Hattori N，et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism [J]. Nature, 1998, 392(6676): 605-608.
[2]	Shinmura H, Hattori N, Mizuno Y, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin－protein ligase [J]. Nat Genet, 2000, 25(3): 302-305.
[3]	Panicker N, Dawson VL, Dawson TM. Activation mechanisms of the E3 ubiquitin ligase parkin [J]. Biochem J, 2017, 474(18): 3075-3086.
[4]	Sauvé V, Sung G, Soya N, et al. Mechanism of parkin activation by phosphorylation [J]. Nat Struct Mol Biol, 2018, 25(7): 623-630.
[5]	Tobias W, Swatek KN, Wagstaff JL，et al. Ubiquitin Ser65 phosphorylation affects ubiquitin structure, chain assembly and hydrolysis [J]. EMBO J, 2015, 34(3): 307-325.
[6]	Harper JW, Ordureau A, Heo JM. Building and decoding ubiquitin chains for mitophagy [J]. Nat Rev Mol Cell Biol, 2018, 19(2): 93-108.
[7]	Kazlauskaite A, Martinez RJ, Wilkie S，et al. Binding to serine 65－phosphorylated ubiquitin primes parkin for optimal PINK1－dependent phosphorylation and activation [J]. EMBO Rep, 2015, 16(8): 939-954.
[8]	Pickrell AM, Youle RJ. The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson′s disease [J]. Neuron, 2015, 85(2): 257-273.
[9]	Jooho S, Seok KH, Hochul K，et al. PARIS (ZNF746) repression of PGC－1α contributes to neurodegeneration in Parkinson′s disease [J]. Cell, 2016, 144(5): 689-702.
[10]	Shires SE, Kitsis RN, Gustafsson AB. Beyond mitophagy: the diversity and complexity of parkin function [J]. Circ Res, 2017, 120(8): 1234-1236.
[11]	Exner N, Lutz AK, Haass C，et al. Mitochondrial dysfunction in Parkinson′s disease: molecular mechanisms and pathophysiological consequences [J]. EMBO J, 2012, 31(14): 3038-3062.
[12]	Bhargava P, Schnellmann RG. Mitochondrial energetics in the kidney [J]. Nat Rev Nephrol, 2017, 13(10): 629-646.
[13]	Rub C, Wilkening A, Voos W. Mitochondrial quality control by the Pink1/parkin system [J]. Cell Tissue Res, 2016, 367(1): 1-13.
[14]	Ni HM, Willams JA, Ding WX. Mitochondrial dynamics and mitochondrial quality control [J]. Redox Biol, 2015, 4: 6-13.
[15]	Narres M, Claessen H, Droste S，et al. The incidence of end－stage renal disease in the diabetic (compared to the non－diabetic) population: a systematic review [J]. PLoS One, 2016, 11(1): e0147329.
[16]	Saxena S, Mathur A, Kakkar P. Critical role of mitochondrial dysfunction and impaired mitophagy in diabetic nephropathy [J]. J Cell Physiol, 2019, 234(11): 19223-19236.
[17]	Ming Z, Usman IM, Lin S，et al. Disruption of renal tubular mitochondrial quality control by myo－inositol oxygenase in diabetic kidney disease [J]. J Am Soc Nephrol, 2015, 26(6): 1304-1321.
[18]	Kaiffeng G, Junxi L, Yan H，et al. Protective role of PGC－1α in diabetic nephropathy is associated with the inhibition of ROS through mitochondrial dynamic remodeling [J]. PLoS One, 2015, 10(4): e0125176.
[19]	Chen K, Dai H, Yuan J，et al. Optineurin－mediated mitophagy protects renal tubular epithelial cells against accelerated senescence in diabetic nephropathy [J]. Cell Death Dis, 2018, 9(2): 105.
[20]	袁俊杰，陈客宏，林利容，等. 泛素连接酶Parkin的表达与糖尿病肾病肾间质损伤的关系[J]. 第三军医大学学报，2017, 39(4): 349-354.
[21]	Tang C, Han H, Yan M, et al. PINK1－PRKN/PARK2 pathway of mitophagy is activated to protect against renal ischemia－reperfusion injury [J]. Autophagy, 2018, 14(5): 880-897.
[22]	Lin Q, Li S, Jiang N，et al. PINK1－parkin pathway of mitophagy protects against contrast－induced acute kidney injury via decreasing mitochondrial ROS and NLRP3 inflammasome activation [J]. Redox Biol, 2019, 26: 101254.
[23]	Zhao C, Chen Z, Xu X，et al. Pink1/parkin－mediated mitophagy play a protective role in cisplatin induced renal tubular epithelial cells injury [J]. Exp Cell Res, 2017, 350(2): 390-397.
[24]	Szeto HH, Liu S, Soong Y，et al. Mitochondria protection after acute ischemia prevents prolonged upregulation of IL－1β and IL－18 and arrests CKD [J]. J Am Soc Nephrol, 2017, 28(5): 1437-1449.
[25]	Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson′s disease [J]. Physiol Rev, 2011, 91(4): 1161-1218.
[26]	Kramer ER. The neuroprotective and regenerative potential of parkin and GDNF/Ret signaling in the midbrain dopaminergic system [J]. Neural Regen Res, 2015, 10(11): 1752-1753.
[27]	Song M, Dorn GW 2nd. Mitoconfusion: noncanonical functioning of dynamism factors in static mitochondria of the heart [J]. Cell Metab, 2015, 21(2): 195-205.
[28]	Kubli DA, Quinsay MN, Gustafsson AB. Parkin deficiency results in accumulation of abnormal mitochondria in aging myocytes [J]. Commun Integr Biol, 2013, 6(4): e24511.
[29]	Debapriya D, Riccardo C, Roberto B，et al. Contribution of impaired mitochondrial autophagy to cardiac aging: mechanisms and therapeutic opportunities [J]. Circ Res, 2012, 110(8): 1125-1138.
[30]	Hoshino A, Mita Y, Okawa Y，et al. Cytosolic p53 inhibits Parkin－mediated mitophagy and promotes mitochondrial dysfunction in the mouse heart [J]. Nat Commun, 2013, 4: 2308.
[31]	Janicki JS, Brower GL. The role of myocardial fibrillar collagen in ventricular remodeling and function [J]. J Card Fail, 2002, 8(6 Suppl): S319-S325.
[32]	Selvaraju V, Taylor BS, Shasha M，et al. Somatic mutations of the Parkinson′s disease－associated gene PARK2 in glioblastoma and other human malignancies [J]. Nat Genet, 2010, 42(1): 77-82.
[33]	Lee SB, Kim JJ, Nam HJ, et al. Parkin regulates mitosis and genomic stability through Cdc20/Cdh1 [J]. Mol Cell, 2015, 60(1): 21-34.
[34]	Devine MJ, Helene PF, Wood NW. Parkinson′s disease and cancer: two wars, one front [J]．Nat Rev Cancer, 2011, 11(11): 812-823.
[35]	Cen Z, Meihua L, Rui W，et al. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect [J]. Proc Natl Acad Sci USA, 2011, 108(39): 16259-16264.
[36]	Liu J, Zhang C, Zhao Y，et al. Parkin targets HIF－1alpha for ubiquitination and degradation to inhibit breast tumor progression [J]. Nat Commun, 2017, 8(1): 1823.
[37]	Lee MH, Cho Y, Jung BC，et al. Parkin induces G2/M cell cycle arrest in TNF－alpha－treated HeLa cells[J]. Biochem Biophys Res Commun, 2015, 464(1): 63-69.
[38]	Carroll R, Hollville E, Martin S. Parkin sensitizes toward apoptosis induced by mitochondrial depolarization through promoting degradation of Mcl－1 [J]. Cell Rep, 2014, 9(4): 1538-1553.
[39]	Araya J, Tsubouchi K, Sato N，et al. PRKN－regulated mitophagy and cellular senescence during COPD pathogenesis [J]. Autophagy, 2019, 15(3): 510-526.
[40]	Lee S, She J, Deng B，et al. Multiple－level validation identifies PARK2 in the development of lung cancer and chronic obstructive pulmonary disease [J]. Oncotarget, 2016, 7(28): 44211-44223.

Please choose a citation manager

Content to export